Appendix 4C and Quarterly Report for Dec 2024 Quarter

• Quarterly cash receipts of $3.89 million, up 36% vs PCP
• Record monthly sales of $3 million, with 56% from Wellnex Life's brands
• 1H FY25 sales up 112% to $11.94 million, with brand sales up 182%

Wellnex Life Limited (ASX:WNX) has reported strong operational and financial results for the quarter ended 31 December 2024 (Q2 FY25). The company recorded cash receipts of $3.9 million, an increase of 36% compared to the prior corresponding period (Q2 FY24: $2.85 million), with an additional $1.2 million received in January 2025 from November sales. Wellnex Life achieved consecutive months of sales in excess of $3 million, with 56% of those sales generated from the company's high-margin brands. This contributed to Wellnex Life generating sales of $11.94 million in 1H FY25, an increase of 112% compared to the prior corresponding period (1H FY24: $5.63 million). Sales from Wellnex Life's brands were up 182%, while IP Licensing sales increased by 64%. The company also delivered its first product for the UK market to Haleon, a significant milestone for its global expansion. Wellnex Life continues to progress its proposed dual listing on the London Stock Exchange, with the appointment of UK-based broker SP Angel as joint broker to the UK raise.

Wellnex Life reported record sales of $11.94 million in 1H FY25, up 112% compared to the prior corresponding period. This was driven by a 182% increase in brand sales to $8.47 million and a 64% increase in IP Licensing sales to $3.47 million.

Wellnex Life is focused on accelerating its global expansion, with the proposed dual listing on the London Stock Exchange and the successful delivery of its first product to the UK market. The company is well-positioned to continue its strong growth trajectory, leveraging its diversified product portfolio and expanding distribution channels.